Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer

E Vlachou, BA Johnson III, E Baraban… - American Society of …, 2024 - ascopubs.org
Urothelial cancer (UC) is the most common histology seen in bladder tumors. The 2022
WHO classification of urinary tract tumors includes a list of less common subtypes (formerly …

[HTML][HTML] Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives

WA Kwon, MK Lee - Cancers, 2024 - mdpi.com
Cisplatin-based chemotherapy has long been the standard first-line (1L) treatment for
metastatic urothelial carcinoma (mUC). However, up to 50% of patients with mUC may be …

Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract

MJ Moussa, GC Tabet, AO Siefker‐Radtke… - Cancer …, 2025 - Wiley Online Library
Introduction Small cell neuroendocrine carcinoma of the urinary tract (SCNEC‐URO) has an
inferior prognosis compared to conventional urothelial carcinoma (UC). Here, we evaluate …

Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy

MJ Moussa, J Khandelwal, NR Wilson, SA Naik… - Current …, 2024 - mdpi.com
Small cell bladder cancer (SCBC) is a rare and aggressive disease, often treated with
platinum/etoposide-based chemotherapy. Key molecular drivers include the inactivation of …